Chest
Volume 113, Issue 3, March 1998, Pages 696-702
Journal home page for Chest

Clinical Investigations: Tumors and Masses
Localization of Bronchial Intraepithelial Neoplastic Lesions by Fluorescence Bronchoscopy

https://doi.org/10.1378/chest.113.3.696Get rights and content
Under a Creative Commons license
open archive

Background

In the treatment of lung cancer, the best outcome is achieved when the lesion is discovered in the intraepithelial (preinvasive) stage. However, intraepithelial neoplastic lesions are difficult to localize by conventional white-light bronchoscopy (WLB).

Objective

To determine if autofluorescence bronchoscopy, when used as an adjunct to WLB, could improve the bronchoscopist's ability to locate and remove biopsy specimens from areas suspicious of intraepithelial neoplasia as compared with WLB alone.

Method

A multicenter clinical trial was conducted in seven institutions in the United States and Canada. WLB followed by fluorescence examination with the light-induced fluorescence endoscopy (LIFE) device was performed in 173 subjects known or suspected to have lung cancer. Biopsy specimens were taken from all areas suspicious of moderate dysplasia or worse on WLB and/or LIFE examination. In addition, random biopsy specimens were also taken from other parts of the bronchial tree.

Results

The relative sensitivity of WLB+LIFE vs WLB alone was 6.3 for intraepithelial neoplastic lesions and 2.71 when invasive carcinomas were also included. The positive predictive value was 0.33 and 0.39 and the negative predictive value was 0.89 and 0.83, respectively, for WLB+LIFE and WLB alone.

Conclusion

Autofluorescence bronchoscopy, when used as an adjunct to standard WLB, enhances the bronchoscopist's ability to localize small neoplastic lesions, especially intraepithelial lesions that may have significant implication in the management of lung cancer in the future.

Key words

autofluorescence
bronchoscopy
early detection
lung neoplasm

Cited by (0)

Partially supported by Xillix Technologies Corp. The Colorado site was also partially supported by the Lurrg Cancer SPORE grant from the National Cancer Institute (No. P50-CA58187), the University of Colorado Cancer Center, and the Department of Veterans Affairs. The Pennsylvania Hospital site was partially supported by the Pennsylvania Hospital Eichler Laser Center and a grant from the Betz Foundation (No. 660300).